Cargando…
A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma
PURPOSE: Neoadjuvant chemoradiation has become the standard treatment in locally advanced rectal cancer (LARC) and improves local control. This study explored the feasibility of an intensified chemoradiation treatment followed by one cycle of capecitabine before surgery for LARC. METHODS AND MATERIA...
Autores principales: | Zhu, Ji, Gu, Weilie, Lian, Peng, Sheng, Weiqi, Cai, Gang, Shi, Debing, Cai, Sanjun, Zhang, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680166/ https://www.ncbi.nlm.nih.gov/pubmed/23718210 http://dx.doi.org/10.1186/1748-717X-8-130 |
Ejemplares similares
-
Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study
por: Zhu, Ji, et al.
Publicado: (2014) -
CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer
por: Cai, Gang, et al.
Publicado: (2015) -
Utility of Restaging MRI Following Neoadjuvant Chemoradiotherapy for Stage II-III Rectal Adenocarcinoma
por: Aryan, Mahmoud, et al.
Publicado: (2021) -
Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021) -
Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)
por: Wang, Jingwen, et al.
Publicado: (2019)